RegeNer8, the N8 Centre for Translational Regenerative Medicine, aims to accelerate the development of regenerative technologies.
RegeNer8, the N8 Centre for Translational Regenerative Medicine, bridges the gap between the N8 Universities of Durham, Lancaster, Leeds, Liverpool, Manchester, Newcastle, Sheffield and York and the regenerative medicine industry in the North of England. Its aim is to accelerate the development of regenerative technologies.
RegeNer8 is a virtual technology market and development centre which adds value by:
?RegeNer8 builds upon the extensive research activities of the Northern Universities (currently, over £100 million). It focuses on partnerships with industry and clinicians to translate basic research into novel regenerative products and therapies, which will provide economic and societal benefits to the North of England.? Prof. John Fisher, Deputy Vice-Chancellor of Leeds University and Academic Director of RegeNer8
RegeNer8?s aim is to improve the global competitiveness of the northern regenerative medicine industry, through:
Regenerative medicine aims to replace or repair diseased or damaged body parts. It is a highly multidisciplinary area incorporating aspects of engineering, cell biology and materials science.
Regenerative medicine encompasses: Cell therapy, Tissue engineering, Regenerative drugs and Devices. It currently represents a very small, emergent sector with the potential to be hugely disruptive. The North hosts significant industry activity in regenerative medicine including: Pharma (Astra Zeneca, Sanofi-aventis); Medical Devices (Smith & Nephew, Johnson & Johnson); and Biotech SMEs (Intercytex, Renovo, Axordia, ReInnervate, Tissue Regenix, Neotherix).
Major barriers to market are (identified in a survey of industry partners): Safety and regulatory issues, Funding and Uncertain business models.
For further information, contact:
Added the 29 August 2009 in category Innovation UK Vol5-1